Clinical Application of 68 Ga-Pentixafor PET/CT for the Detection of Thymoma: A Pilot Study.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI:10.1097/RLU.0000000000005770

Rongxi Wang, Xuehan Gao, Xingtong Peng, Jiarou Wang, Jialin Xiang, Linlin Li, Chenhao Jia, Jingci Chen, Xin Du, Chao Guo, Xiaoyun Zhou, Yumin Zheng, Zhaohui Zhu, Yeye Chen, Shanqing Li

{"title":"Clinical Application of 68 Ga-Pentixafor PET/CT for the Detection of Thymoma: A Pilot Study.","authors":"Rongxi Wang, Xuehan Gao, Xingtong Peng, Jiarou Wang, Jialin Xiang, Linlin Li, Chenhao Jia, Jingci Chen, Xin Du, Chao Guo, Xiaoyun Zhou, Yumin Zheng, Zhaohui Zhu, Yeye Chen, Shanqing Li","doi":"10.1097/RLU.0000000000005770","DOIUrl":null,"url":null,"abstract":"Purpose: This study was designed to evaluate 68 Ga-pentixafor, which targets C-X-C chemokine receptor 4 (CXCR4), in the noninvasive diagnosis of thymomas.Patients and methods: With institutional review board approval and signed informed consent, 32 patients with thymic masses were enrolled in this study, and all patients underwent 68 Ga-pentixafor PET/CT scans.Results: Among the 28 patients included in the analysis, 13 patients were diagnosed with thymomas, 9 patients with cysts, and 6 patients with other anterior mediastinal masses. 68 Ga-pentixafor identified all patients with thymomas (13/13, 100%), and the mean SUV max in all 13 thymomas lesions was 13.96±8.20, which was significantly higher than that in patients with cysts (1.54±0.88) and other anterior mediastinal masses (2.59±1.68), respectively ( P <0.001).Conclusions: The preliminary study indicates the diagnostic utility of 68 Ga-pentixafor in thymomas and the differential diagnostic ability of 68 Ga-pentixafor in thymomas, thymic cysts and other benign anterior mediastinal masses.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"388-393"},"PeriodicalIF":9.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005770","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study was designed to evaluate 68 Ga-pentixafor, which targets C-X-C chemokine receptor 4 (CXCR4), in the noninvasive diagnosis of thymomas.

Patients and methods: With institutional review board approval and signed informed consent, 32 patients with thymic masses were enrolled in this study, and all patients underwent 68 Ga-pentixafor PET/CT scans.

Results: Among the 28 patients included in the analysis, 13 patients were diagnosed with thymomas, 9 patients with cysts, and 6 patients with other anterior mediastinal masses. 68 Ga-pentixafor identified all patients with thymomas (13/13, 100%), and the mean SUV max in all 13 thymomas lesions was 13.96±8.20, which was significantly higher than that in patients with cysts (1.54±0.88) and other anterior mediastinal masses (2.59±1.68), respectively ( P <0.001).

Conclusions: The preliminary study indicates the diagnostic utility of 68 Ga-pentixafor in thymomas and the differential diagnostic ability of 68 Ga-pentixafor in thymomas, thymic cysts and other benign anterior mediastinal masses.

查看原文本刊更多论文

68ga - pentxafor PET/CT检测胸腺瘤的临床应用：初步研究。

目的：本研究旨在评价靶向C-X-C趋化因子受体4 （CXCR4）的68ga - pentxafor在胸腺瘤无创诊断中的价值。患者和方法：经机构审查委员会批准并签署知情同意书，32例胸腺肿块患者入组本研究，所有患者均接受68ga - pentxapet /CT扫描。结果：纳入分析的28例患者中，胸腺瘤13例，囊肿9例，其他前纵隔肿块6例。68Ga-pentixafor识别出所有胸腺瘤患者（13/ 13,100 %），13例胸腺瘤病变的平均SUVmax为13.96±8.20，显著高于囊肿（1.54±0.88）和其他前纵隔肿块（2.59±1.68）(p)。初步研究表明68Ga-pentixafor在胸腺瘤中的诊断价值，以及68Ga-pentixafor在胸腺瘤、胸腺囊肿及其他良性前纵隔肿块中的鉴别诊断能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.